VARLITINIB (ASLAN001)

Target: Pan-HER | Disease State: Cancer

Introduction / Brief Description

Varlintinib, a novel, oral pan-HER inhibitor, was invented by Array and licensed to ASLAN Pharmaceuticals. Varlintinib has shown clinical activity in both HER2-positive and EGFR-positive tumors. In January 2018, Array granted ASLAN full global rights to develop, manufacture and commercialize varlintinib. The 2018 agreement replaces and supersedes the July 2011 agreement, between Array and ASLAN. Varlintinib is being developed for biliary tract, gastric, colorectal and breast cancer.

Clinical Trials

To learn more about varlitinib clinical trials, click here.

Publications and Presentations

ASLAN001

06/17/2013

Heterocyclic Compounds GRC

Process Research and Development of the Tyrosine Kinase Inhibitor Varlitinib Tosylate (ARRY-543 Ditosylate)

D. D. Hennings, et al.

ASLAN001

04/02/2011

American Association for Cancer Research Annual Meeting

Selective Inhibitors of the ErbB-Family of Receptor Tyrosine Kinase

E. Wallace, Ph.D.

ASLAN001

04/20/2010

American Association for Cancer Research, Chemical and Biological Aspects of Inflammation and Cancer

Pan-ErbB Inhibition by ARRY-334543 is Superior to Selective ErbB Inhibition in a Preclinical Model that Signals Through Multiple ErbB Receptors

R. Blackwell, et al.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials only.